Develops engineered precision biologics using proprietary expanded genetic code technology. Focuses on creating antibody-drug conjugates (ADCs) targeting various cancers. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 10% a year over the last 3 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $7.4M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 41 buys and 20 sells. Management buying with its own money is usually read as a good sign.
A loss of $78.0M against $7.4M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.